Spironolactone has been shown beneficial in CHF and many of the same mechanisms are at plan in RV failure from pulmonary hypertension.
Again, no clear evidence whether this is a useful treatment or not, and no evidence to guide... more »
What are the regional variations in cellular and molecular characteristics (from epigenetics to microbiome) in the lung, and what controls these variations?
What is the role of lung stem/progenitor cells in disease?
Which diseases involve stem cell defects?
What molecular and cellular pathways explain the sex-specific differences in the prevalence, severity, and progression of lung diseases?
Does the treatment of gastroesophageal reflux disease improve outcomes in patients with IPF?
How can the safety, dosing and benefits of existing therapies for sickle cell disease such as hydroxyurea, be optimized in order to increase its efficacy and improve patient adherence?
Understanding injury, regeneration and repair of the developing lung.
Do the non-pharmacological interventions of pulmonary rehabilitation and supplemental oxygen for exertional hypoxemia improve quality of life and functional status in patients with chronic fibrotic ILD?
How do lung progenitors recognize stem cell niches, and what cell-cell interactions mediate normal repair?
Can a multipronged approach to reversing/repairing scar tissue in pulmonary fibrosis be deployed as soon as possible?